ArticleJournal of neuroinflammation2025
LARP7 protects against ischemic brain injury by modulating NLRP3 deacetylation to suppress neuronal pyroptosis.
Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundIschemic stroke is a leading cause of morbidity and mortality worldwide, yet available therapeutic strategies remain limited. La ribonucleoprotein domain family member 7 (LARP7), a critical regulator of RNA stability and transcriptional control, participates in cellular stress responses and inflammatory modulation. Emerging evidence suggests LARP7's involvement in neuroinflammation and neuronal survival, yet its role in ischemic stroke pathogenesis is still poorly understood.
methodsWe systematically investigated LARP7 expression in patients with acute ischemic stroke (AIS), mice subjected to middle cerebral artery occlusion/reperfusion (MCAO/R), and neurons exposed to oxygen-glucose deprivation/reoxygenation (OGD/R). To elucidate the role of LARP7 in ischemic stroke, we generated neuron-specific LARP7 knockout mice, and employed a lentiviral delivery system for neuronal LARP7 overexpression. Protein interactions between LARP7-Sirt1 and Sirt1-NLRP3 were assessed using co-immunoprecipitation, proximity ligation assay, domain deletion analysis, and acetyl-proteomics. Furthermore, a potential LARP7 activator was identified through virtual screening, and its activation efficacy and neuroprotective effects were evaluated.
resultsLARP7 was markedly downregulated in the ischemic brain tissues from AIS patients and MCAO/R mice, as well as in OGD/R neurons. Neuronal LARP7 deficiency exacerbated neuronal pyroptosis and neurological deficits following ischemic stroke, which could be partially rescued by pharmacological activation of Sirt1. Mechanistically, LARP7's C-terminal domain interacted with the N-terminal domain of Sirt1 to enhance Sirt1 deacetylase activity, which facilitated NLRP3 deacetylation at K21/K22/K24, thereby inhibiting inflammasome assembly and subsequent neuronal pyroptosis. Furthermore, sorafenib tosylate was identified as a potential LARP7 activator with demonstrated neuroprotective effects.
conclusionLARP7 enhances Sirt1 deacetylase activity to regulate NLRP3 deacetylation, thereby inhibiting inflammasome assembly and neuronal pyroptosis after ischemic stroke. Targeting LARP7 could represent a promising therapeutic strategy for ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.